> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Repligen Says BioLife Deal Puts 2027 Revenue Above $1 Billion, But Calls It Not Formal Guidance
- URL: https://www.bullished.co/repligen-says-biolife-deal-puts-2027-revenue-above-1-billion-but-calls-it-not-formal-01990904/
- Published: 2026-10-27T13:27:09.000Z
- Updated: 2026-10-29T18:20:03.000Z
- Description: The CEO said at least 25% reported growth is in reach next year, with formal guidance due toward the end of February.
- Author: Matteo Parrino
- Tags: Earnings, RGEN, Industry: Healthcare

[Repligen](https://www.bullished.co/tag/rgen/) is positioned to grow reported revenue at least 25% in 2027 and pass $1 billion, CEO Olivier Loeillot said on the company's third-quarter earnings call Tuesday, after it [closed the BioLife acquisition](https://www.globenewswire.com/news-release/2026/10/27/3388843/24603/en/repligen-reports-third-quarter-2026-financial-results-and-updates-full-year-2026-financial-guidance.html?ref=bullished.co) this month. He stressed it is not formal guidance.

## A framework, not a forecast

Loeillot said the 25% figure assumes market growth of high single digits and no material change in foreign exchange rates. Answering a JPMorgan analyst, he said the framework "is not a formal guidance for 2027," and that the company gives guidance toward the end of February and aims to do the same this year.

BioLife, he said, has been consolidated for only about 20 days, and the company is still working through its budget. He named two swing factors for market growth: capital equipment orders and FDA approvals.

Repligen makes the filtration, chromatography, process analytics and protein products that drugmakers use to manufacture biological drugs.

## The $24 million question

The updated 2026 outlook assumes about $24 million of BioLife revenue for the fourth quarter. A Wolfe Research analyst noted that looked flat against roughly $25 million a year earlier for an asset that had been growing about 20%, and asked whether it was a conservative haircut.

CFO Jason Garland said BioLife shipped a "disproportionate amount of sales" in the first days of October, so "it really isn't the math of a flat year over year." Loeillot said that adding the $24 million to early-October and third-quarter sales, the company is aiming for $114 million of BioLife revenue for 2026, above the midpoint of BioLife's last guidance.

Garland said the company remains on track for at least five cents of accretion to earnings per share in 2027\. For 2026 he guided adjusted EPS of [$2.05 to $2.09](https://finance.yahoo.com/markets/stocks/articles/repligen-q3-earnings-snapshot-110935702.html?ref=bullished.co) and said BioLife is slightly dilutive in the fourth quarter.

## Synergies and the quarter

Loeillot said public-company and certain leadership costs, already captured, represent more than half of the anticipated year-one operating-expense synergies.

Third-quarter revenue was a record [$209 million](https://www.globenewswire.com/news-release/2026/10/27/3388843/24603/en/repligen-reports-third-quarter-2026-financial-results-and-updates-full-year-2026-financial-guidance.html?ref=bullished.co), up 12.5% organically, and full-year revenue guidance rose to $844 million to $852 million.

The next formal number is the 2027 guidance, which Repligen aims to give around the end of February.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Repligen: Q3 Earnings Snapshot](https://finance.yahoo.com/markets/stocks/articles/repligen-q3-earnings-snapshot-110935702.html?ref=bullished.co) — Associated Press
- [Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates](https://finance.yahoo.com/healthcare/articles/repligen-rgen-q3-earnings-revenues-111503600.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Repligen Reports Third Quarter 2026 Financial Results and](https://www.globenewswire.com/news-release/2026/10/27/3388843/24603/en/repligen-reports-third-quarter-2026-financial-results-and-updates-full-year-2026-financial-guidance.html?ref=bullished.co) — globenewswire.com

### More on Repligen

- [Repligen CEO Says Equipment 'Tap' Is Only 5-10% Open, Even After Five-Year High In Orders](https://www.bullished.co/repligen-ceo-says-equipment-tap-is-only-5-10-open-even-after-five-year-high-in-orders-cd78f39d/)
- [Repligen Lifts 2026 Revenue Outlook To $844 Million-$852 Million, Yet A $41.2 Million Writedown Drives A Quarterly Loss](https://www.bullished.co/repligen-lifts-2026-revenue-outlook-to-844-million-852-million-yet-a-41-2-million-0a3c1ffb/)
- [Repligen Closes BioLife Deal: $11.25 In Cash And 0.1442 Repligen Shares For Each BioLife Share](https://www.bullished.co/repligen-closes-biolife-deal-11-25-in-cash-and-0-1442-repligen-shares-for-each-biolife-1a5d37a5/)

[All Repligen (RGEN) coverage →](https://www.bullished.co/tag/rgen/)